



## Prior Authorization Oncology – Mekinist® (trametinib tablets)

### Table of Contents

National Formulary Medical Necessity .....	1
Conditions Not Covered.....	2
Background.....	3
References .....	4
Revision History .....	4

### Product Identifier(s)

31572

#### INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

### National Formulary Medical Necessity

**Cigna covers trametinib (Mekinist®) as medically necessary when the following criteria are met for FDA Indications or Other Uses with Supportive Evidence:**

Prior Authorization is recommended for prescription benefit coverage of Mekinist. All approvals are provided for the duration noted below.

#### FDA Indication(s)

- Melanoma.** Approve for 3 years if the individual meets the following (A, B, and C):
  - Individual is ≥ 18 years of age; AND
  - Individual has unresectable, advanced (including Stage III or Stage IV disease), or metastatic melanoma; AND  
Note: This includes adjuvant treatment in individuals with Stage III disease with no evidence of disease post-surgery.
  - Individual has BRAF V600 mutation-positive disease.

2. **Non-Small Cell Lung Cancer.** Approve for 3 years if the individual meets the following (A, B, and C):
- A) Individual is  $\geq 18$  years of age; AND
  - B) Individual has BRAF V600E mutation-positive disease; AND
  - C) The medication is prescribed in combination with Tafenlar (dabrafenib capsules).
3. **Thyroid Carcinoma, Anaplastic.** Approve for 3 years if the individual meets the following (A, B, C, and D):
- A) Individual is  $\geq 18$  years of age; AND
  - B) Individual has locally advanced or metastatic anaplastic disease; AND
  - C) Individual has BRAF V600 mutation-positive disease; AND
  - D) The medication is prescribed in combination with Tafenlar (dabrafenib capsules), unless intolerant.

#### Other Uses with Supportive Evidence

4. **Biliary Tract Cancer.** Approve for 3 years if the individual meets the following (A, B, C, and D):
- A) Individual is  $\geq 18$  years of age; AND
  - B) Individual has tried at least one systemic chemotherapy regimen; AND
  - C) Individual has BRAF V600 mutation-positive disease; AND
  - D) The medication is prescribed in combination with Tafenlar (dabrafenib capsules).
5. **Central Nervous System Cancer.** Approve for 3 years if the individual meets the following (A, B, C, and D):
- A) Individual is  $\geq 18$  years of age; AND
  - B) The medication is being used for one of the following situations (i, ii, or iii):
    - i. Adjuvant treatment of one of the following conditions (a, b, or c):
      - a) Pilocytic astrocytoma; OR
      - b) Pleomorphic xanthoastrocytoma; OR
      - c) Ganglioglioma; OR
    - ii. Recurrent disease for one of the following conditions (a, b, or c):
      - a) Low-grade glioma; OR
      - b) Anaplastic glioma; OR
      - c) Glioblastoma; OR
    - iii. Brain metastases from melanoma; AND
  - C) Individual has BRAF V600 mutation-positive disease; AND
  - D) The medication is prescribed in combination with Tafenlar (dabrafenib capsules).
6. **Histiocytic Neoplasm.** Approve for 3 years if the individual meets the following (A, B, and C):
- 4. Individual is  $\geq 18$  years of age; AND
  - 5. Individual meets one of the following (i, ii, or iii):
    - a. Individual has Langerhans cell histiocytosis and one of the following (a, b, or c):
      - a) Multisystem disease; OR
      - b) Pulmonary disease; OR
      - c) Central nervous system lesions; OR
    - b. Individual has Erdheim-Chester disease; OR
    - c. Individual has Rosai-Dorfman disease; AND
  - 6. Individual has BRAF V600 mutation-positive disease.
7. **Ovarian/Fallopian Tube/Primary Peritoneal Cancer.** Approve for 3 years if the individual meets the following (A, B, and C):
- A) Individual is  $\geq 18$  years of age; AND
  - B) Individual has recurrent disease; AND
  - C) The medication is used for low-grade serous carcinoma.

## Conditions Not Covered

Trametinib (Mekinist) is considered experimental, investigational or unproven for ANY other use.

## Background

### Overview

Mekinist, a kinase inhibitor, is indicated for the treatment of patients with the following conditions:<sup>1</sup>

- **Melanoma**, in the following situations:
  - As a single agent for unresectable or metastatic disease with a *BRAF V600E* or *V600K* mutation as detected by an FDA-approved test.
  - In combination with Tafenlar® (dabrafenib tablets), for treatment of unresectable or metastatic disease with a *BRAF V600E* or *V600K* mutation as detected by an FDA-approved test.
  - In combination with Tafenlar for adjuvant treatment of patients with a *BRAF V600E* or *V600K* mutation as detected by an FDA-approved test, and involvement of lymph nodes, following complete resection.
- **Non-small cell lung cancer**, in combination with Tafenlar, for treatment of disease that has the *BRAF V600E* mutation as detected by an FDA-approved test.
- **Thyroid cancer**, in combination with Tafenlar, for treatment of patients with locally advanced or metastatic anaplastic disease with *BRAF V600E* mutation and with no satisfactory locoregional treatment options.

### Guidelines

National Comprehensive Cancer Network (NCCN) guidelines support use of Mekinist in multiple cancers.

- **Central Nervous System Cancers** (version 1.2021 – June 4, 2021): Guidelines recommend a BRAF/MEK inhibitor combination (i.e., Tafenlar/Mekinist or Zelboraf® [vemurafenib tablets]/Cotellic® [cobimetinib tablets]) for treatment of *BRAF V600E* activation mutation in the following situations: adjuvant treatment of pilocytic astrocytoma, pleomorphic xanthoastrocytoma, or ganglioglioma; recurrent or progressive low-grade glioma; recurrent anaplastic glioma; and recurrent glioblastoma.<sup>7</sup> BRAF/MEK combination therapy is also recommended for melanoma with brain metastases.
- **Hepatobiliary Cancers** (version 3.2021 – June 15, 2021): Guidelines recommend Tafenlar + Mekinist for subsequent therapy for biliary tract cancers, if the patient has a *BRAF V600E* mutation.<sup>8</sup>
- **Histiocytic Neoplasms** (version 1.2021 – March 1, 2021): NCCN recommends Cotellic (preferred) or Mekinist (other recommended regimen) for histiocytic neoplasms (if there is a MAP kinase pathway mutation, or no detectable mutation, or testing is not available) for the following types: Langerhans cell histiocytosis (including multisystem, pulmonary or central nervous system lesions), Erdheim-Chester disease, and Rosai-Dorfman disease.<sup>6</sup>
- **Melanoma, Cutaneous** (version 2.2021 – February 19, 2021): Guidelines for cutaneous disease recommend BRAF/MEK inhibitor combinations among the preferred therapies for first-line and subsequent treatment of metastatic or unresectable melanoma with a *V600*-activating mutation.<sup>2</sup> While combination BRAF/MEK inhibition is preferred, if a combination is contraindicated, monotherapy with a BRAF inhibitor is a recommended option. Tafenlar + Mekinist is also recommended in guidelines as adjuvant therapy (including for nodal recurrence) in some patients with Stage III disease, including use post-surgery or use after complete lymph node dissection. If unacceptable toxicity to Tafenlar/Mekinist, other BRAF/MEK combinations can be considered.
- **Non-Small Cell Lung Cancer** (version 5.2021 – June 15, 2021): Guidelines list Tafenlar + Mekinist among the first-line therapy and subsequent therapy options for tumors with a *BRAF* mutation.<sup>3</sup> NCCN also notes that monotherapy with a BRAF inhibitor (Tafenlar or Zelboraf) is a treatment option when combination therapy is not tolerated.
- **Thyroid Cancer** (version 1.2021 – April 9, 2021): Guidelines list Tafenlar + Mekinist as a treatment option for metastatic anaplastic thyroid cancer with a *BRAF* mutation.<sup>4</sup>
- **Ovarian Cancer, Including Fallopian Tube and Primary Peritoneal** (version 1.2021 – February 26, 2021): Guidelines recommend Mekinist among the targeted therapy options for recurrent low-grade serous disease.<sup>5</sup>

## References

1. Mekinist® tablets [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; May 2021.
2. The NCCN Melanoma Clinical Practice Guidelines in Oncology (Version 2.2021 – July 27, 2021). © 2021 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org/>. Accessed on July 27, 2021.
3. The NCCN Non-Small Cell Lung Cancer Clinical Practice Guidelines in Oncology (Version 5.2021 – June 15, 2021). © 2021 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org/>. Accessed on July 15, 2021.
4. The NCCN Thyroid Carcinoma Clinical Practice Guidelines in Oncology (Version 1.2021 – April 9, 2021). © 2021 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org/>. Accessed on July 16, 2021.
5. The NCCN Ovarian Cancer Clinical Practice Guidelines in Oncology (Version 1.2021 – February 26, 2021). © 2021 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org/>. Accessed on July 31, 2021.
6. The NCCN Histiocytic Neoplasms Clinical Practice Guidelines in Oncology (Version 1.2021 – March 1, 2021). © 2021 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org/>. Accessed on July 25, 2021.
7. The NCCN Central Nervous System Cancers Clinical Practice Guidelines in Oncology (Version 1.2021 – June 4, 2021). © 2021 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org/>. Accessed on July 25, 2021.
8. The NCCN Hepatobiliary Cancers Clinical Practice Guidelines in Oncology (Version 3.2021 – June 15, 2021). © 2021 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org/>. Accessed on July 31, 2021.

## Revision History

Type of Revision	Summary of Changes	Review Date
Annual Revision	<b>Melanoma:</b> A requirement was added that the patient is ≥ 18 years of age. <b>Non-Small Cell Lung Cancer:</b> A requirement was added that the patient is ≥ 18 years of age. <b>Thyroid Cancer, Anaplastic:</b> A requirement was added that the patient is ≥ 18 years of age. <b>Biliary Tract Cancer:</b> This condition of approval was added. <b>Central Nervous System Cancer:</b> This condition of approval was added. <b>Histiocytic Neoplasm:</b> This condition of approval was added. <b>Ovarian/Fallopian Tube/Primary Peritoneal Cancer:</b> A requirement was added that the patient is ≥ 18 years of age.	08/04/2021

“Cigna Companies” refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Cigna Behavioral Health, Inc., Cigna Health Management, Inc., QualCare, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. © 2021 Cigna.